Delving into the Latest Updates on OX2 Therapeutics, Inc. with Synapse

Overview

Tags

Nervous System Diseases

Neoplasms

Other Diseases

Recombinant polypeptide

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Recombinant polypeptide	1

Top 5 Target	Count

CD200(OX-2 membrane glycoprotein)	1

This is a single center Phase I study of a new adjuvant CD200 activation receptor ligand, CD200AR-L, in combination with imiquimod and GBM6-AD vaccine to treat malignant glioma in children and young adults.
The primary objective of this study is to determine the maximum tolerated dose (MTD) of CD200AR-L when given with a fixed dose of GBM6-AD vaccine, imiquimod, and a single dose of radiation for patients with recurrent High Grade Glioma (HGG) or following standard of care therapy radiation therapy for newly diagnosed Newly Diagnosed Diffuse Midline Glioma/Diffuse Intrinsic Pontine Glioma (DIPG/DMG).

Start Date15 Mar 2024

Sponsor / Collaborator

OX2 Therapeutics, Inc.Startup

NCT04642937 / Active, not recruitingPhase 1

Study of CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent Glioblastoma

This is a single-center, open-label, dose-range finding Phase I study of hP1A8, a new adjuvant CD200 activation receptor ligand (CD200AR-L), in combination with imiquimod and the GBM6-AD vaccine to treat recurrent glioblastoma (GBM) in adults.

Start Date01 Dec 2020

Sponsor / Collaborator

OX2 Therapeutics, Inc.Startup

100 Clinical Results associated with OX2 Therapeutics, Inc.

Login to view more data

0 Patents (Medical) associated with OX2 Therapeutics, Inc.

Login to view more data

100 Deals associated with OX2 Therapeutics, Inc.

Login to view more data

100 Translational Medicine associated with OX2 Therapeutics, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

Login to view more data